Synopsis
The applicant, a 56-year-old defense contractor and former U.S. Army member, faced security concerns under Guidelines H (Drug Involvement and Substance Misuse) and E (Personal Conduct) due to his admitted marijuana use while holding a security clearance. The judge found that the applicant did not mitigate the concerns, leading to a denial of his security clearance.
Why the applicant was denied
- Applicant admitted to purchasing and using marijuana while holding a security clearance.
- Applicant tested positive for marijuana in July 2023 as part of a drug-free workplace program.
- Applicant's drug use raised questions about his reliability, trustworthiness, and judgment.
Conditions referenced
- H.25.araisedAny Substance Misuse
- H.25.braisedTesting Positive for an Illegal Drug
- H.25.fraisedIllegal Drug Use While Granted Access to Classified Information
- E.16.craisedCredible Adverse Information in Several Adjudicative Issue Areas
- H.26.arejectedBehavior Unlikely to RecurApplicant's long-term marijuana use while holding a security clearance undermined this condition.
- H.26.brejectedAcknowledgment of Drug Involvement and Actions Taken to Overcome the ProblemNo evidence of a pattern of abstinence or significant mitigating actions.
- E.17.crejectedOffense Is Minor or Unlikely to RecurThe applicant's drug use was not infrequent and occurred while holding a sensitive position.
- E.17.erejectedPositive Steps to Reduce VulnerabilityApplicant's conduct did not demonstrate sufficient positive steps to mitigate concerns.
Key rule quoted
“[A]ny doubt concerning personnel being considered for national security eligibility will be resolved in favor of the national security.”
Procedural posture
- SOR issuedFeb 7, 2025
- Answer filedMar 25, 2025Requested decision based on written record.
- Hearing held—No hearing; decision based on written record.
- Decision dateFeb 17, 2026
Cite for
- Denial of Security Clearance Due to Drug Involvement Under Guideline H
- Impact of Personal Conduct on Security Clearance Eligibility Under Guideline E
- Importance of Mitigating Conditions in Drug-related Cases